Concepedia

Matthew Dearman

MD

Statistics

Publications

4

Citations

146

H-Index

4

Active since

2014

Affiliations

AstraZeneca (Sweden)(Current)

Bayer (Germany)

Matthew Dearman is an author at AstraZeneca (Sweden) specializing in pharmacotherapy, medicine, and pharmacology.

Top concepts

Publications per year

2014–2019

4

Publications

4

Discovery of a Novel Oral Glucocorticoid Receptor Modulator (AZD9567) with Improved Side Effect Profile

Lena Ripa, K. A. P. Edman, Matthew Dearman et al. · Journal of Medicinal Chemistry · 2018 · 73 citations · Full text

, , +19

Efficacious Inhaled PDE4 Inhibitors with Low Emetic Potential and Long Duration of Action for the Treatment of COPD

Chris De Savi, Rhona J. Cox, Daniel J. Warner et al. · Journal of Medicinal Chemistry · 2014 · 32 citations · Full text

, , +15

Effects of a selective glucocorticoid receptor modulator (AZD9567) versus prednisolone in healthy volunteers: two phase 1, single-blind, randomised controlled trials

Tove Hegelund Myrbäck, Susanne Prothon, K. A. P. Edman et al. · The Lancet Rheumatology · 2019 · 24 citations

, , +6

Discovery of indazole ethers as novel, potent, non-steroidal glucocorticoid receptor modulators

Martin Hemmerling, K. A. P. Edman, Matti Lepistö et al. · Bioorganic & Medicinal Chemistry Letters · 2016 · 17 citations · Full text

, , +5

1–4 of 4